Dengue vaccine could be ready by 2015: Sanofi

Jun 10, 2011

French drugs group Sanofi said Friday that its vaccine against dengue, a mosquito-borne infection that kills thousands of people around the world each year, could be launched in about four years.

"The vaccine could be available... around 2015," Jean Lang, head of at the group's subsidiary Sanofi-Pasteur, told reporters in Bangkok.

The launch date is dependent on regulatory approval in each country based on the results of trials.

The vaccine is the first for dengue to undergo advanced "Phase III" clinical trials -- the final stage before the results are submitted for regulatory approval.

About 4,000 children in the central Thai province of Ratchaburi, one of the worst affected areas in the country, are participating in a study that aims to establish the efficacy of the vaccine.

Dengue causes severe, in about 50 million people every year, mainly in developing countries. There are four strains, one of which is a potentially lethal type.

Dengue has reemerged in recent years as a serious public health threat in . There is currently no treatment, cure or vaccine.

Explore further: FDA approves AbbVie combo hepatitis C treatment

add to favorites email to friend print save as pdf

Related Stories

Thailand developing dengue vaccine: researcher

Feb 22, 2011

Researchers in Thailand say they have developed a prototype vaccine against dengue fever and will conduct further tests with the aim of bringing it to market within a decade.

US researchers hopeful for dengue vaccine

Feb 17, 2011

Promising advances have been made in the testing of possible vaccines to prevent the mosquito-borne dengue virus, which kills 25,000 people every year, researchers said Thursday.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

7 minutes ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.